MediWound Ltd. (MDWD)
MDWD Stock Price Chart
Explore MediWound Ltd. interactive price chart. Choose custom timeframes to analyze MDWD price movements and trends.
MDWD Company Profile
Discover essential business fundamentals and corporate details for MediWound Ltd. (MDWD) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
20 Mar 2014
Employees
121.00
Website
https://www.mediwound.comCEO
Ofer Gonen
Description
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
MDWD Financial Timeline
Browse a chronological timeline of MediWound Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.76, while revenue estimate is $2.59m.
Earnings released on 27 May 2026
EPS came in at -$0.23 surpassing the estimated -$0.65 by +64.62%, while revenue for the quarter reached $1.48m , missing expectations by -56.19%.
Earnings released on 5 Mar 2026
EPS came in at -$0.56 surpassing the estimated -$0.65 by +13.85%, while revenue for the quarter reached $1.87m , missing expectations by -55.47%.
Earnings released on 20 Nov 2025
EPS came in at -$0.24 surpassing the estimated -$0.81 by +70.37%, while revenue for the quarter reached $5.43m , beating expectations by +160.10%.
Earnings released on 14 Aug 2025
EPS came in at -$1.23 falling short of the estimated -$0.55 by -123.64%, while revenue for the quarter reached $5.71m , missing expectations by -13.02%.
Earnings released on 21 May 2025
EPS came in at -$0.07 surpassing the estimated -$0.65 by +89.23%, while revenue for the quarter reached $3.96m , missing expectations by -31.35%.
Earnings released on 19 Mar 2025
EPS came in at -$0.36 surpassing the estimated -$0.59 by +38.98%, while revenue for the quarter reached $5.84m , beating expectations by +11.14%.
Earnings released on 26 Nov 2024
EPS came in at -$0.98 falling short of the estimated -$0.44 by -122.73%, while revenue for the quarter reached $4.36m , missing expectations by -25.32%.
Earnings released on 14 Aug 2024
EPS came in at -$0.68 falling short of the estimated -$0.42 by -61.90%, while revenue for the quarter reached $5.06m , missing expectations by -15.76%.
Earnings released on 29 May 2024
EPS came in at -$0.39 surpassing the estimated -$0.40 by +2.50%, while revenue for the quarter reached $4.96m , beating expectations by +6.30%.
Earnings released on 21 Mar 2024
EPS came in at -$0.19 surpassing the estimated -$0.23 by +17.39%, while revenue for the quarter reached $5.34m , beating expectations by +0.34%.
Earnings released on 21 Nov 2023
EPS came in at -$0.24 surpassing the estimated -$0.44 by +45.45%, while revenue for the quarter reached $4.78m , missing expectations by -5.61%.
Earnings released on 15 Aug 2023
EPS came in at $0.10 surpassing the estimated -$0.40 by +125.00%, while revenue for the quarter reached $4.77m , missing expectations by -3.38%.
Earnings released on 30 May 2023
EPS came in at -$0.44 falling short of the estimated -$0.30 by -46.67%, while revenue for the quarter reached $3.80m , missing expectations by -26.23%.
Earnings released on 16 Mar 2023
EPS came in at -$1.18 falling short of the estimated -$0.59 by -100.00%, while revenue for the quarter reached $11.62m , beating expectations by +76.03%.
Stock split effective on 20 Dec 2022
Shares were split 1 : 7 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 15 Nov 2022
EPS came in at -$0.91 falling short of the estimated -$0.70 by -30.00%, while revenue for the quarter reached $5.80m , beating expectations by +26.08%.
Earnings released on 9 Aug 2022
EPS came in at -$0.84 falling short of the estimated -$0.68 by -23.53%, while revenue for the quarter reached $4.67m , missing expectations by -11.53%.
Earnings released on 17 May 2022
EPS came in at -$0.84 falling short of the estimated -$0.76 by -10.53%, while revenue for the quarter reached $4.41m , beating expectations by +2.64%.
Earnings released on 17 Mar 2022
EPS came in at -$1.05 matching the estimated -$1.05, while revenue for the quarter reached $5.49m , missing expectations by -0.89%.
Earnings released on 16 Nov 2021
EPS came in at -$0.84 surpassing the estimated -$0.90 by +6.67%, while revenue for the quarter reached $6.37m , beating expectations by +15.23%.
Earnings released on 10 Aug 2021
EPS came in at -$0.84 falling short of the estimated -$0.48 by -75.00%, while revenue for the quarter reached $6.06m , beating expectations by +7.58%.
MDWD Stock Performance
Access detailed MDWD performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
